Safety, Tolerability, and Pharmacokinetics of BAP5191 in Healthy Adults Following Topical Application of Repeat Doses

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
All enrolled participants will be randomized to 3 cohorts with 8 participants each and will receive BAP5191 and placebo topically on a square of 121 cm2 each in the left and right scapula region daily for 28 days, with a 28-d safety follow-up. The squares will be covered with a semi-occlusive patch. The doses will escalate from Cohort 1 to Cohort 2 to Cohort 3.
Epistemonikos ID: 582934aa57e267998e3a93f0bd9df4cf74f76381
First added on: Feb 19, 2024